Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Tadekinig alfa in IL-18 Driven Monogenic Autoinflammatory Conditions
2023-504534-21-00Phase 3Completed
- Sponsor
- AB2 Bio Ltd.
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of tadekinig alfa in Interleukin-18 driven monogenic autoinflammatory disease, sponsored by AB2 Bio Ltd. Primary endpoint: Safety and tolerability of Tadekinig alfa. Started Jul 2023; status: completed.
02
Drugs
tadekinig alfa
03
Conditions
Interleukin-18 driven monogenic autoinflammatory disease
Beyond the preview
Go deeper on 2023-504534-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504534-21-00.